Zur Geschichte der Juden in Lublin

Abraham Lewinsky

Aus dem Hildesheimer Stadtarchive

Abraham Lewinsky

Der jüdische Hofbankier der Magdeburger Erzbischöfe im 14. Jahrh.

Abraham Lewinsky

Eine Ode Wolf Heidenheims aus dem Jahre 1795

L. Lewinsky

Drei deutsche Juden betreffende päpstliche Urkunden aus dem Jahre 1372

Abraham Lewinsky

Regesten zur Geschichte der Juden in der Provinz Sachsen während des Mittelalters

Abraham Lewinsky

Ein Beitrag zur Geschichte der Juden in Braunschweig während des 15. und 16. Jahrhunderts

Abraham Lewinsky

Patenting genes and gene sequences: Analysis of public health implications and the law

At issue is whether or not isolated DNA is patent eligible under the U.S. Patent Law and the implications of that determination on public health. The U.S. Patent and Trademark Office has issued patents on DNA since the 1980s, and scientists and researchers have proceeded under that milieu since that time. Today, genetic research and testing related to the human breast cancer genes BRCA1 and BRCA2 is conducted within the framework of seven patents that were issued to Myriad Genetics and the University of Utah Research Foundation between 1997 and 2000. In 2009, suit was filed on behalf of multiple researchers, professional associations and others to invalidate fifteen of the claims underlying those patents. The Court of Appeals for the Federal Circuit, which hears patent cases, has invalidated claims for analyzing and comparing isolated DNA but has upheld claims to isolated DNA. The specific issue of whether isolated DNA is patent eligible is now before the Supreme Court, which is expected to decide the case by year's end. In this work, a systematic review was performed to determine the effects of DNA patents on various stakeholders and, ultimately, on public health; and to provide a legal analysis of the patent eligibility of isolated DNA and the likely outcome of the Supreme Court's decision. ^ A literature review was conducted to: first, identify principle stakeholders with an interest in patent eligibility of the isolated DNA sequences BRCA1 and BRCA2; and second, determine the effect of the case on those stakeholders. Published reports that addressed gene patents, the Myriad litigation, and implications of gene patents on stakeholders were included. Next, an in-depth legal analysis of the patent eligibility of isolated DNA and methods for analyzing it was performed pursuant to accepted methods of legal research and analysis based on legal briefs, federal law and jurisprudence, scholarly works and standard practice legal analysis. ^ Biotechnology, biomedical and clinical research, access to health care, and personalized medicine were identified as the principle stakeholders and interests herein. Many experts believe that the patent eligibility of isolated DNA will not greatly affect the biotechnology industry insofar as genetic testing is concerned; unlike for therapeutics, genetic testing does not require tremendous resources or lead time. The actual impact on biomedical researchers is uncertain, with greater impact expected for researchers whose work is intended for commercial purposes (versus basic science). The impact on access to health care has been surprisingly difficult to assess; while invalidating gene patents might be expected to decrease the cost of genetic testing and improve access to more laboratories and physicians' offices that provide the test, a 2010 study on the actual impact was inconclusive. As for personalized medicine, many experts believe that the availability of personalized medicine is ultimately a public policy issue for Congress, not the courts. ^ Based on the legal analysis performed in this work, this writer believes the Supreme Court is likely to invalidate patents on isolated DNA whose sequences are found in nature, because these gene sequences are a basic tool of scientific and technologic work and patents on isolated DNA would unduly inhibit their future use. Patents on complementary DNA (cDNA) are expected to stand, however, based on the human intervention required to craft cDNA and the product's distinction from the DNA found in nature. ^ In the end, the solution as to how to address gene patents may lie not in jurisprudence but in a fundamental change in business practices to provide expanded licenses to better address the interests of the several stakeholders. ^

LexA chimeras reveal the function of Drosophila Fos as a context-dependent transcriptional activator

The transcriptional activation potential of proteins can be assayed in chimeras containing a heterologous DNA-binding domain that mediates their recruitment to reporter genes. This approach has been widely used in yeast and in transient mammalian cell assays. Here, we applied it to assay the transactivation potential of proteins in transgenic Drosophila embryos. We found that a chimera between the DNA-binding bacterial LexA protein and the transactivation domain from yeast GAL4 behaved as a potent synthetic activator in all embryonic tissues. In contrast, a LexA chimera containing Drosophila Fos (Dfos) required an unexpected degree of context to function as a transcriptional activator. We provide evidence to suggest that this context is provided by Djun and Mad (a Drosophila Smad), and that these partner factors need to be activated by signaling from Jun N-terminal kinase and decapentaplegic, respectively. Because Dfos behaves as an autonomous transcriptional activator in more artificial assays systems, our data suggest that context-dependence of transcription factors may be more prevalent than previously thought.

Protein disulfide isomerase: the structure of oxidative folding

Cellular functions hinge on the ability of proteins to adopt their correct folds, and misfolded proteins can lead to disease. Here, we focus on the proteins that catalyze disulfide bond formation, a step in the oxidative folding pathway that takes place in specialized cellular compartments. In the endoplasmic reticulum of eukaryotes, disulfide formation is catalyzed by protein disulfide isomerase (PDI); by contrast, prokaryotes produce a family of disulfide bond (Dsb) proteins, which together achieve an equivalent outcome in the bacterial periplasm. The recent crystal structure of yeast PDI has increased our understanding of the function and mechanism of PDI. Comparison of the structure of yeast PDI with those of bacterial DsbC and DsbG reveals some similarities but also striking differences that suggest directions for future research aimed at unraveling the catalytic mechanism of disulfide bond formation in the cell.

Aluminium hydroxide stabilised MnFe2O4 and Fe3O4 nanoparticles as dual-modality contrasts agent for MRI and PET imaging

Magnetic nanoparticles (NPs) MnFe2O4 and Fe3O4 were stabilised by depositing an Al(OH)3 layer via a hydrolysis process. The particles displayed excellent colloidal stability in water and a high affinity to [18F]-fluoride and bisphosphonate groups. A high radiolabeling efficiency, 97% for 18F-fluoride and 100% for 64Cu-bisphosphonate conjugate, was achieved by simply incubating NPs with radioactivity solution at room temperature for 5min. The properties of particles were strongly dependant on the thickness and hardness of the Al(OH)3 layer which could in turn be controlled by the hydrolysis method. The application of these Al(OH)3 coated magnetic NPs in molecular imaging has been further explored. The results demonstrated that these NPs are potential candidates as dual modal probes for MR and PET. In vivo PET imaging showed a slow release of 18F from NPs, but no sign of efflux of 64Cu. © 2014 The Authors.

A munkavállalói tudás hasznosításának új lehetősége felsőoktatási keretek között

A szerzők tanulmányukban áttekintést kívánnak adni az előzetes tudás, a munkahelyi tanulás és a tudás felsőoktatási keretekben való elismeréséről. Céljuk az, hogy ráirányítsák a szervezetek figyelmét egy olyan törvény által biztosított lehetőségre, amelynek bevezetése érdeke a munkaerő-piaci szereplőknek is. Hazánkban az egyetemek/főiskolák még csak ismerkednek az előzetes tudás elismerésének elveivel, de a kutatások szerint nagyon gyenge az érdekeltségük. Ez a megközelítés változhat, ha a szervezetek, a szakmai kamarák megfogalmazzák a tudáselismerés iránti igényüket, s ezzel felgyorsítják a törvény által már biztosított validáció széles körű elterjedését.

A közlekedési eszközpark és infrastruktúra hasznos élettartamát tudományos alapon növelő technológia kidolgozása a BKV ZRt. számára

A budapesti közösségi közlekedési eszközpark jelentős része meghaladta beszerzéskor tervezett hasznos élettartamát. Ezen eszközök továbbüzemeltetése a jelenleg rendelkezésre álló információk alapján még hosszú ideig szükséges, ezért – a hasznos élettartam növelésére vonatkozó komplex és teljes körű módszertan hiányában – 2012-ben a Budapesti Közlekedési Zártkörűen Működő Részvénytársaság (továbbiakban BKV Zrt., Társaság) vezetése szakmai döntést hozott e hiány pótlását szolgáló, tudományosan megalapozott rendszer kidolgozására. A hasznos élettartamot tudományos alapon növelő módszertan és technológia kidolgozására vonatkozó együttműködés eredményeképpen előállt az úgynevezett tudományos alapú továbbüzemeltetési protokoll (továbbiakban: TTP) modell. Az új, időtálló modell a továbbüzemeltetés feltételeit műszaki, biztonsági és gazdasági szempontok komplex rendszerbe integrálásával, objektív értékelési módszertan alapján határozza meg, és ezáltal a Társaság menedzsmentje szerint vállalhatónak ítélt szintre mérsékelve az üzemeltetői kockázatok és felelősség mértékét.